Integrated Filing — IndAS

General information about company
Scrip Code	506197
NSE Symbol	BLISSGVS
MSEI Symbol	NOTLISTED
ISIN	INE416D01022
Name of company	BLISS GVS PHARMA LIMITED
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	12-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	05-May-2025
Description of presentation currency	INR (in Actuals)
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Pharmaceutical & Healthcare
Start date and time of board meeting	12-May-2025   15:56:00
End date and time of board meeting	12-May-2025   18:30:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	2022-01-29
Indicate Company website link for updated RPT policy of the Company	https://blissgvs.com/policies-and-codes1/
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No
The Company has not made any defaults.

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	1560024000	6672046000
	Other income	93608000	362165000
	Total income	1653632000	7034211000
2	Expenses
(a)	Cost of materials consumed	687859000	3394744000
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	91883000	66323000
(d)	Employee benefit expense	252246000	994178000
(e)	Finance costs	12998000	65838000
(f)	Depreciation, depletion and amortisation expense	74345000	270472000
(f)	Other Expenses
1	Freight outward	77159000	317994000
2	Business Development expenses	82499000	261595000
3	ECL Expenses	-16150000	83390000
4	Repairs and Maintenance	53495000	154972000
5	Power and Fuel	21786000	97556000
6	Sales Promotion expenses	8587000	33449000
7	Travelling and Conveyance expenses	8677000	43677000
8	Provision for Doubtful Balance	90792000	90792000
9	Legal and Professional charges	28001000	52819000
10	Other Expenses	35888000	164701000
	Total other expenses	390734000	1300945000
	Total expenses	1510065000	6092500000
3	Total profit before exceptional items and tax	143567000	941711000
4	Exceptional items	0	0
5	Total profit before tax	143567000	941711000
6	Tax expense
7	Current tax	39489000	299914000
8	Deferred tax	-10443000	-47890000
9	Total tax expenses	29046000	252024000
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	114521000	689687000
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	114521000	689687000
17	Other comprehensive income net of taxes	-1428000	-5572000
18	Total Comprehensive Income for the period	113093000	684115000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent
	Total profit or loss, attributable to non-controlling interests
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent
	Total comprehensive income for the period attributable to owners of parent non-controlling interests
21	Details of equity share capital
	Paid-up equity share capital	105370000	105370000
	Face value of equity share capital	1	1
27	Details of debt securities
22	Reserves excluding revaluation reserve		10480961000
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	1.08	6.56
	Diluted earnings (loss) per share from continuing operations	1.07	6.5
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	1.08	6.56
	Diluted earnings (loss) per share from continuing and discontinued operations	1.07	6.5
24	Debt equity ratio	0.0005	0.0005
25	Debt service coverage ratio	0.0201	0.028
26	Interest service coverage ratio	0.1205	0.153
27	Disclosure of notes on financial results		1.tThe above audited financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 12, 2025. These audited financial results have been prepared in accordance with recognition and measurement principles of Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and the other accounting principles generally accepted in India. n2.tThe above audited financial results for the quarter and year ended March 31, 2025 are prepared in compliance with Ind AS, which have been audited by the statutory auditors of the Company. The statutory auditors have issued audit reports with unmodified opinion on the audited standalone and consolidated financial results. n3.tAs the Company's business activity falls within a single operating segment viz Pharmaceutical and Healthcare, no segment information is disclosed. n4.tEmployee Benefit Expenses includes Share Based Payment expense on account of ESOP Scheme, 2019 of Re. 414.00 Lakh (Year ended March 31, 2024 Re. 381.57 Lakh) as per Ind AS 102 Share based Payment for the year ended March 31, 2025. n5.tDuring the year ended March 31, 2025, the Company has allotted 6,79,450 equity shares of Re. 1 each fully paid, on exercise of stock options by employees in accordance with the Company's ESOP Scheme, 2019. From the total 59,74,000 number of options granted, the outstanding number of options as at March 31, 2025 are 13,83,750. n6.tThe Board of Directors has recommended final dividend of Re. 0.50 paisa per share. The payment is subject to approval of shareholders in the ensuing Annual General Meeting of the Company. n7.tThe Consolidated Financial Results includes the Results of the following entities: nName of the Companyt% of ShareholdingtConsolidated as nKremoint Pharma Pvt. Ltd.t70%tSubsidiary nAsterisk Lifesciences Ltd.t100%tSubsidiary nBliss GVS International Pte. Ltd.t100%tSubsidiary nEipii Exports Pvt. Ltd.t70%tStep-Down Subsidiary nGreenlife Bliss Healthcare Ltd.t51%tStep-Down Subsidiary nAsterisk Lifesciences (GH) Ltd.t100%tStep-Down Subsidiary n n n8.tThe Board of Directors in its meeting held on May 12, 2025 has approved the sale of 51% stake in its step-down subsidiary Greenlife Bliss Healthcare Ltd, Nigeria held by its Subsidiary Bliss GVS International Pte Ltd, Singapore to non-controlling shareholder for a total consideration of USD 13,00,000 subject to necessary regulatory and other approvals. The transaction is expected to be completed in H1 FY 2025-26. n9.tThe Board of Directors in its meeting held on May 12, 2025 has approved the issuance of 12,10,000 equity shares as Sweat equity shares for non-cash consideration having the face value of Re. 1 each to Mr. Gagan Harsh Sharma - Managing Director and Mr. Vishal Rao - Vice President of the Company having Fair Market Value/Volume Weighted Average Price of Re. 148.72 per share. These shares were allotted in compliance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 and subject to shareholder's approval. n10.tThe Company has classified Assets located at Ambernath, Maharashtra comprising of Land and Building as held for sale as on March 31, 2025 consequent to the MOU entered by its Subsidiary Company Kremoint Pharma Pvt Ltd, India. The transaction is expected to be completed by September 30, 2025. n11.tThe Company has invested in, given loans, accrued interest and due thereon and trade receivables from one of its subsidiary and its step-down subsidiaries aggregating to Re. 15,255.83 Lakh. This subsidiary had a consolidated negative net worth. In view of macro-economics business scenarios, during the previous year the management has assessed these investments and loans for impairment and based thereof, investments in/ loan given to Company's subsidiary Bliss GVS International Pte Ltd including step-down subsidiaries viz Greenlife Bliss Healthcare Ltd, Asterisk Lifesciences DRC and Asterisk Lifesciences (GH) Ltd had been impaired and accordingly an amount of Re. 4,108.61 Lakh and Re. 2,919.61 Lakh in standalone and consolidated financial results/statements respectively had been recognised as an exceptional item for the quarter and year ended March 31, 2024 respectively. n12.tThe figures for the quarter ended March 31 are the balancing figures between audited figures in respect of the year ended March 31 and the published year to date unaudited figures for the nine months ended ended December 31 of the respective financial year. n n

Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets
1	Non-current assets
	Property, plant and equipment	3676647000
	Capital work-in-progress	205818000
	Investment property	6829000
	Goodwill	0
	Other intangible assets	2206000
	Intangible assets under development	0
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets
	Non-current investments	186895000
	Trade receivables, non-current	0
	Loans, non-current	0
	Other non-current financial assets	228128000
	Total non-current financial assets	415023000
	Deferred tax assets (net)	90928000
	Other non-current assets	122605000
	Total non-current assets	4520056000
2	Current assets
	Inventories	819388000
	Current financial asset
	Current investments	0
	Trade receivables, current	4282519000
	Cash and cash equivalents	68280000
	Bank balance other than cash and cash equivalents	1642817000
	Loans, current	369891000
	Other current financial assets	193629000
	Total current financial assets	6557136000
	Current tax assets (net)	23945000
	Other current assets	276432000
	Total current assets	7676901000
3	Non-current assets classified as held for sale	0
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	Total assets	12196957000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	105370000
	Other equity	10480961000
	Total equity attributable to owners of parent	10586331000
	Non controlling interest
	Total equity	10586331000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	196729000
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0
	Total Trade payable	0
	Other non-current financial liabilities	124714000
	Total non-current financial liabilities	321443000
	Provisions, non-current	43639000
	Deferred tax liabilities (net)	0
	Deferred government grants, Non-current	0
	Other non-current liabilities	0
	Total non-current liabilities	365082000
	Current liabilities
	Current financial liabilities
	Borrowings, current	313360000
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	64514000
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	538643000
	Total Trade payable	603157000
	Other current financial liabilities	268673000
	Total current financial liabilities	1185190000
	Other current liabilities	55430000
	Provisions, current	4924000
	Current tax liabilities (Net)	0
	Deferred government grants, Current	0
	Total current liabilities	1245544000
3	Liabilities directly associated with assets in disposal group classified as held for sale	0
4	Regulatory deferral account credit balances and related deferred tax liability	0
	Total liabilities	1610626000
	Total equity and liabilites	12196957000
	Disclosure of notes on assets and liabilities	Textual Information(1)

Text Block

Textual Information(1)

1.tThe above audited financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 12, 2025. These audited financial results have been prepared in accordance with recognition and measurement principles of Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and the other accounting principles generally accepted in India. n2.tThe above audited financial results for the quarter and year ended March 31, 2025 are prepared in compliance with Ind AS, which have been audited by the statutory auditors of the Company. The statutory auditors have issued audit reports with unmodified opinion on the audited standalone and consolidated financial results. n3.tAs the Company's business activity falls within a single operating segment viz Pharmaceutical and Healthcare, no segment information is disclosed. n4.tEmployee Benefit Expenses includes Share Based Payment expense on account of ESOP Scheme, 2019 of Re. 414.00 Lakh (Year ended March 31, 2024 Re. 381.57 Lakh) as per Ind AS 102 Share based Payment for the year ended March 31, 2025. n5.tDuring the year ended March 31, 2025, the Company has allotted 6,79,450 equity shares of Re. 1 each fully paid, on exercise of stock options by employees in accordance with the Company's ESOP Scheme, 2019. From the total 59,74,000 number of options granted, the outstanding number of options as at March 31, 2025 are 13,83,750. n6.tThe Board of Directors has recommended final dividend of Re. 0.50 paisa per share. The payment is subject to approval of shareholders in the ensuing Annual General Meeting of the Company. n7.tThe Consolidated Financial Results includes the Results of the following entities: nName of the Companyt% of ShareholdingtConsolidated as nKremoint Pharma Pvt. Ltd.t70%tSubsidiary nAsterisk Lifesciences Ltd.t100%tSubsidiary nBliss GVS International Pte. Ltd.t100%tSubsidiary nEipii Exports Pvt. Ltd.t70%tStep-Down Subsidiary nGreenlife Bliss Healthcare Ltd.t51%tStep-Down Subsidiary nAsterisk Lifesciences (GH) Ltd.t100%tStep-Down Subsidiary n n n8.tThe Board of Directors in its meeting held on May 12, 2025 has approved the sale of 51% stake in its step-down subsidiary Greenlife Bliss Healthcare Ltd, Nigeria held by its Subsidiary Bliss GVS International Pte Ltd, Singapore to non-controlling shareholder for a total consideration of USD 13,00,000 subject to necessary regulatory and other approvals. The transaction is expected to be completed in H1 FY 2025-26. n9.tThe Board of Directors in its meeting held on May 12, 2025 has approved the issuance of 12,10,000 equity shares as Sweat equity shares for non-cash consideration having the face value of Re. 1 each to Mr. Gagan Harsh Sharma - Managing Director and Mr. Vishal Rao - Vice President of the Company having Fair Market Value/Volume Weighted Average Price of Re. 148.72 per share. These shares were allotted in compliance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 and subject to shareholder's approval. n10.tThe Company has classified Assets located at Ambernath, Maharashtra comprising of Land and Building as held for sale as on March 31, 2025 consequent to the MOU entered by its Subsidiary Company Kremoint Pharma Pvt Ltd, India. The transaction is expected to be completed by September 30, 2025. n11.tThe Company has invested in, given loans, accrued interest and due thereon and trade receivables from one of its subsidiary and its step-down subsidiaries aggregating to Re. 15,255.83 Lakh. This subsidiary had a consolidated negative net worth. In view of macro-economics business scenarios, during the previous year the management has assessed these investments and loans for impairment and based thereof, investments in/ loan given to Company's subsidiary Bliss GVS International Pte Ltd including step-down subsidiaries viz Greenlife Bliss Healthcare Ltd, Asterisk Lifesciences DRC and Asterisk Lifesciences (GH) Ltd had been impaired and accordingly an amount of Re. 4,108.61 Lakh and Re. 2,919.61 Lakh in standalone and consolidated financial results/statements respectively had been recognised as an exceptional item for the quarter and year ended March 31, 2024 respectively. n12.tThe figures for the quarter ended March 31 are the balancing figures between audited figures in respect of the year ended March 31 and the published year to date unaudited figures for the nine months ended ended December 31 of the respective financial year. n n

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Jan-2025	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
	Total Segment Revenue
	Less: Inter segment revenue
	Revenue from operations
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
	Total Profit before tax
	i. Finance cost
	ii. Other Unallocable Expenditure net off Unallocable income
	Profit before tax
3	(Segment Asset - Segment Liabilities)
	Segment Asset
	Total Segment Asset
	Un-allocable Assets	null	null
	Net Segment Asset	null	null
4	Segment Liabilities
	Segment Liabilities
	Total Segment Liabilities
	Un-allocable Liabilities	null	null
	Net Segment Liabilities	null	null
	Disclosure of notes on segments

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	Remeasurement of Defined Benefit Plan	-1907000	-7445000
	Total Amount of items that will not be reclassified to profit and loss	-1907000	-7445000
2	Income tax relating to items that will not be reclassified to profit or loss	-479000	-1873000
3	Amount of items that will be reclassified to profit and loss
	Total Amount of items that will be reclassified to profit and loss
4	Income tax relating to items that will be reclassified to profit or loss	0	0
5	Total Other comprehensive income	-1428000	-5572000

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Audited
D	Nature of report standalone or consolidated			Standalone
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			941711000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			65838000
	Adjustments for decrease (increase) in inventories			-64691000
	Adjustments for decrease (increase) in trade receivables, current			-368484000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			169455000
	Adjustments for decrease (increase) in other non-current assets			0
	Adjustments for other financial assets, non-current			-4096000
	Adjustments for other financial assets, current			0
	Adjustments for other bank balances			0
	Adjustments for increase (decrease) in trade payables, current			62347000
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			-31444000
	Adjustments for increase (decrease) in other non-current liabilities			0
	Adjustments for depreciation and amortisation expense			270472000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			0
	Adjustments for provisions, current			0
	Adjustments for provisions, non-current			0
	Adjustments for other financial liabilities, current			6125000
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses gains			-13017000
	Adjustments for dividend income			1260000
	Adjustments for interest income			139322000
	Adjustments for share-based payments			41400000
	Adjustments for fair value losses (gains)			0
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			1872000
	Other adjustments to reconcile profit (loss)			0
	Other adjustments for non-cash items			338400000
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			333595000
	Net cash flows from (used in) operations			1275306000
	Dividends received			0
	Interest paid			0
	Interest received			0
	Income taxes paid (refund)			303252000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			972054000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			0
	Other cash receipts from sales of equity or debt instruments of other entities			0
	Other cash payments to acquire equity or debt instruments of other entities			0
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			0
	Proceeds from sales of property, plant and equipment			17720000
	Purchase of property, plant and equipment			685034000
	Proceeds from sales of investment property			0
	Purchase of investment property			0
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			2207000
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			0
	Cash advances and loans made to other parties			0
	Cash receipts from repayment of advances and loans made to other parties			0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			1260000
	Interest received			139587000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			-248577000
	Net cash flows from (used in) investing activities	-777251000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			28862000
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			0
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			0
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			500436000
	Repayments of borrowings			646703000
	Payments of lease liabilities			42845000
	Dividends paid			53948000
	Interest paid			52865000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) financing activities			-267063000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			-72260000
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			0
	Net increase (decrease) in cash and cash equivalents			-72260000
	Cash and cash equivalents cash flow statement at beginning of period			141746000
	Cash and cash equivalents cash flow statement at end of period			69486000